KR20070010161A - 정신분열증 및/또는 당조절 이상 치료방법 - Google Patents

정신분열증 및/또는 당조절 이상 치료방법 Download PDF

Info

Publication number
KR20070010161A
KR20070010161A KR1020067022972A KR20067022972A KR20070010161A KR 20070010161 A KR20070010161 A KR 20070010161A KR 1020067022972 A KR1020067022972 A KR 1020067022972A KR 20067022972 A KR20067022972 A KR 20067022972A KR 20070010161 A KR20070010161 A KR 20070010161A
Authority
KR
South Korea
Prior art keywords
alkyl
hydrogen
formula
compound
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067022972A
Other languages
English (en)
Korean (ko)
Inventor
크레이크 피 스미스
데이비드 이 렘프
베스 보로우스키
사타파나 콩사무트
Original Assignee
아벤티스 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아벤티스 파마슈티칼스 인크. filed Critical 아벤티스 파마슈티칼스 인크.
Publication of KR20070010161A publication Critical patent/KR20070010161A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020067022972A 2004-04-01 2005-04-01 정신분열증 및/또는 당조절 이상 치료방법 Ceased KR20070010161A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55845104P 2004-04-01 2004-04-01
US60/558,451 2004-04-01

Publications (1)

Publication Number Publication Date
KR20070010161A true KR20070010161A (ko) 2007-01-22

Family

ID=34978926

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067022972A Ceased KR20070010161A (ko) 2004-04-01 2005-04-01 정신분열증 및/또는 당조절 이상 치료방법

Country Status (26)

Country Link
US (1) US20070129403A1 (https=)
EP (2) EP1734959B1 (https=)
JP (1) JP2007531730A (https=)
KR (1) KR20070010161A (https=)
CN (1) CN1946399A (https=)
AR (1) AR048197A1 (https=)
AT (1) ATE446754T1 (https=)
AU (1) AU2005231446A1 (https=)
BR (1) BRPI0509512A (https=)
CA (1) CA2561162A1 (https=)
CL (1) CL2009001605A1 (https=)
CY (1) CY1109734T1 (https=)
DE (1) DE602005017373D1 (https=)
DK (1) DK1734959T3 (https=)
DO (1) DOP2005000050A (https=)
ES (1) ES2334241T3 (https=)
GT (1) GT200500063A (https=)
IL (1) IL178168A0 (https=)
MX (1) MXPA06011222A (https=)
PA (1) PA8628601A1 (https=)
PL (1) PL1734959T3 (https=)
PT (1) PT1734959E (https=)
SI (1) SI1734959T1 (https=)
SV (1) SV2006002069A (https=)
TW (1) TW200602040A (https=)
WO (1) WO2005097122A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170017434A (ko) 2015-08-07 2017-02-15 계명대학교 산학협력단 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
JO3032B1 (ar) 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
WO2010068750A2 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
EP2437744B1 (en) * 2009-06-03 2015-06-03 Marquette University Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CN103512972A (zh) * 2013-07-29 2014-01-15 上海交通大学 精神分裂症的生物标志物及其使用方法和应用
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
EP3941352A1 (en) 2019-03-19 2022-01-26 Cambridge Cognition Limited Method and uses of diagnosing and recommending treatment for a psychotic disorder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0287982B1 (en) * 1987-04-24 1994-12-07 Hoechst-Roussel Pharmaceuticals Incorporated N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments
US4970218A (en) 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US5102891A (en) * 1990-07-23 1992-04-07 Hoechst-Roussel Pharmaceuticals Inc. 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US5356910A (en) * 1993-07-19 1994-10-18 Hoechst-Roussel Pharmaceuticals Inc. Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder
DE69621617T2 (de) * 1995-07-27 2003-01-02 Aventis Pharmaceuticals Inc., Bridgewater Verwendung von substituierten und nichtsubstituierten n-(pyrrol-1-yl)pyridinaminen als antikonvulsiva
EP0876379A1 (en) 1996-01-17 1998-11-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
RU2215004C2 (ru) 1997-07-16 2003-10-27 Ново Нордиск А/С Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170017434A (ko) 2015-08-07 2017-02-15 계명대학교 산학협력단 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물

Also Published As

Publication number Publication date
GT200500063A (es) 2005-10-14
SI1734959T1 (sl) 2010-02-26
ATE446754T1 (de) 2009-11-15
PL1734959T3 (pl) 2010-03-31
US20070129403A1 (en) 2007-06-07
CY1109734T1 (el) 2014-09-10
CN1946399A (zh) 2007-04-11
DE602005017373D1 (de) 2009-12-10
EP1734959A2 (en) 2006-12-27
ES2334241T3 (es) 2010-03-08
IL178168A0 (en) 2006-12-31
CA2561162A1 (en) 2005-10-20
DOP2005000050A (es) 2005-11-30
WO2005097122A2 (en) 2005-10-20
EP2138176A1 (en) 2009-12-30
MXPA06011222A (es) 2007-01-16
PA8628601A1 (es) 2006-05-16
PT1734959E (pt) 2009-12-24
JP2007531730A (ja) 2007-11-08
AU2005231446A1 (en) 2005-10-20
WO2005097122A3 (en) 2006-02-02
EP1734959B1 (en) 2009-10-28
SV2006002069A (es) 2006-05-24
TW200602040A (en) 2006-01-16
CL2009001605A1 (es) 2009-11-27
DK1734959T3 (da) 2010-03-08
BRPI0509512A (pt) 2007-09-11
AR048197A1 (es) 2006-04-05

Similar Documents

Publication Publication Date Title
KR20070010161A (ko) 정신분열증 및/또는 당조절 이상 치료방법
TWI519299B (zh) 大麻素與抗精神病藥物組合使用之技術
US20260098052A1 (en) Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same
US9029561B2 (en) TRKB agonists and methods of use
US20100178277A1 (en) Methods and compositions for stimulating cells
US9345694B2 (en) Compounds for enhancing arginase activity and methods of using same
JP2009524676A (ja) 精神分裂病を治療するための方法および組成物
JP2010504338A (ja) 筋萎縮性側索硬化症（ＡＬＳ）の治療のための水素化ピリド［４，３−ｂ］インドール
EP2185150B1 (en) Use of tranilast and derivatives thereof for the therapy of neurological conditions
WO2009155777A1 (zh) 法舒地尔化合物的用途、方法及其药物组合物
US20220265646A1 (en) Piezo agonists for preventing or reverting abnormal amyloid deposition
KR20200101948A (ko) 신경계 질환 치료제
AU2019247871A1 (en) Compositions and methods for increasing remyelination
JP2009534415A (ja) ニューロトロフィン発現に対するａｍｐａ受容体モジュレーターの作用の薬理学的制御
ES2948767T3 (es) Moléculas orgánicas pequeñas para uso en el tratamiento de trastornos neuroinflamatorios
PT1658062E (pt) Derivados de alfa-amino amida úteis como agentes antiinflamatórios
JP2015502941A (ja) 少なくとも１つのｃｎｓ障害の治療、予防、および／または管理のためのルラシドン新規投与レジメンおよびその使用
CN118697754A (zh) 香蒲新苷在制备治疗缺血性脑卒中药物的应用
JP2015052006A (ja) 疼痛制御及び脱髄損傷の回復におけるｎ−２−ヒドロキシ−エチル−ピペラジン−ｎ’−２−エタンスルホン酸（ｈｅｐｅｓ）の役割
TW201932130A (zh) 脂質運載蛋白型前列腺素ｄ２合成酵素產生促進劑
US6350768B1 (en) Combination of riluzole and of gabapentin and its use as a medicament
US20090221610A1 (en) Compositions and Methods for Treating Cognitive Disorders
WO2026017114A1 (zh) 一种苯基嘧啶酮化合物的用途
RU2508096C2 (ru) Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
KOTAGAL et al. 5| PARKINSON SYNDROMES: PROGRESSIVE SUPRANUCLEAR PALSY

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20061101

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20091231

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110706

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20111130

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110706

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I